Related Experiment Video
Updated: Jul 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Pluristem Therapeutics, Inc
1Pluristem Therapeutics, Inc, MATAM Advanced Technology Park #20, Haifa 3190, Israel. bill@pluristem.com
Abstract:
Pluristem Therapeutics, Inc., based in Haifa, Israel, is a regenerative, biotherapeutics Company dedicated to the commercialization of nonpersonalized (allogeneic) cell therapy products. The Company is expanding noncontroversial placental-derived mesenchymal stem cells via a proprietary 3D process, named PluriX, into therapeutics for a variety of degenerative, malignant and autoimmune disorders. Pluristem will be conducting Phase I trials in the USA with its first product, PLX-I, which addresses the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of hematopoietic stem cells contained in umbilical cord blood.
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...
Pleiotropy
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Cytoskeletal Linker Proteins - Plakins

